Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Pharma
J&J bispecific combo delivers 89% PFS benefit in myeloma
An 89% progression-free survival improvement and a 62% overall survival benefit topline Tecvayli and Talvey’s MonumenTAL-6 readout in earlier myeloma.
Angus Liu
Jul 23, 2026 8:30am
AbbVie, Genmab's Epkinly redeems itself in DLBCL
Jun 30, 2026 9:50am
ASCO: Incyte positions Monjuvi combo for first-line DLBCL
May 30, 2026 8:00am
Novartis stands by $5B Pluvicto goal despite EU regulatory setback
Apr 28, 2026 10:10am
Kyowa, Sino Biopharm, Duality—Fierce Pharma Asia
Mar 6, 2026 9:35am
China biotech deals, Shionogi's ALS buy—Fierce Pharma Asia
Jan 9, 2026 3:00am
